AbCellera Biologics Inc. (ABCL)
Pharmaceutical Preparations
Latest Price
$11.17
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
2.94
P/B Ratio
3.79
Valuation metrics
adjust assumptions →Base FCF: $196M (median of recent 5yr)
Growth: 11%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$17.67
+58% upside
Institutional Ownership
38.7% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 33.01M | $259.0M | 10.77% | +2.74M | 2026-06-30 |
| Capital World Investors | 13.59M | $106.0M | 4.43% | +227.3K | 2026-06-30 |
| TWO SIGMA INVESTMENTS, LP | 10.44M | $81.0M | 3.41% | -- | 2026-06-30 |
| TD Waterhouse Canada Inc. | 9.57M | $72.0M | 3.12% | +3.5K | 2026-06-30 |
| BANK OF AMERICA CORP /DE/ | 6.14M | $48.0M | 2.00% | +3.14M | 2026-06-30 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4.32M | $33.0M | 1.41% | -3.26M | 2026-06-30 |
| ArrowMark Colorado Holdings LLC | 4.11M | $32.0M | 1.34% | -- | 2026-06-30 |
| BlackRock, Inc. | 3.81M | $29.0M | 1.24% | -234.9K | 2026-06-30 |
| Driehaus Capital Management LLC | 2.86M | $22.0M | 0.93% | -1.16M | 2026-06-30 |
| CITADEL ADVISORS LLC | 2.75M | $21.0M | 0.90% | +871.3K | 2026-06-30 |